Clinical Trials for Non-Small Cell Lung Cancer

Phase II Study of Adagrasib + Stereotactic Radiosurgery (SRS) for Patients With Metastatic KRAS G12C-mutated NSCLC With Untreated Brain Metastases

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: This trial involves 30 adult patients with stage IV KRAS G12C-mutated NSCLC and untreated brain metastases, assessing the efficacy of combination treatment with the KRAS G12C inhibitor adagrasib and Stereotactic Radiosurgery (SRS).

ClinicalTrials.gov ID: NCT06248606

An Open-label Phase I/IIa Study to Evaluate the Safety and Efficacy of CCS1477 as Monotherapy and in Combination, in Patients With Advanced Solid/Metastatic Tumours.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: This trial targets patients with advanced or metastatic tumors, including metastatic castration-resistant prostate cancer, metastatic breast cancer, and non-small cell lung cancer, evaluating CCS1477, an inhibitor of bromodomains of p300/CBP, both as monotherapy and in combination with therapies like abiraterone and atezolizumab.

ClinicalTrials.gov ID: NCT03568656

A Multicenter, Open-Label Phase 1/2 Trial Evaluating the Safety, Tolerability, and Efficacy of MORAb-202, a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Subjects With Selected Tumor Types

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: The trial enrolls adults with measurable ovarian, endometrial, triple-negative breast, or non-small cell lung cancers to evaluate the safety and efficacy of Farletuzumab Ecteribulin (MORAb-202), an antibody-drug conjugate targeting folate receptor alpha, which delivers eribulin to cancer cells.

ClinicalTrials.gov ID: NCT04300556

ICON-RT: Intracranial Consolidation and Deferral of Radiation Therapy in Patients Receiving Approved CNS-Active Systemic Therapeutics

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: This trial involves patients aged 18 and older with EGFR-mutant NSCLC and measurable brain metastases, examining the efficacy of osimertinib, a CNS-penetrant EGFR TKI, with or without stereotactic radiosurgery (SRS). Participants may be TKI-naïve or have started TKI treatment within the past three months.

ClinicalTrials.gov ID: NCT06741085

Radiation Prior to TKI to Delay Progression in Advanced Driver-Mutated Non-small Cell Lung Cancers (RadiaNCe Lung X)

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: The trial involves treatment-naïve adults with metastatic non-small cell lung cancer featuring actionable driver mutations, using radiation therapy on the primary lung lesion followed by tyrosine kinase inhibitor (TKI) therapy to delay disease progression. Radiation doses range from 24-60 Gy, and TKI treatment targets genetic mutations driving cancer growth.

ClinicalTrials.gov ID: NCT06305715

A Phase 3, Multicenter, Randomized, Open-label Study Evaluating Efficacy of Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Subjects With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers, Negative for PD-L1, and Positive for KRAS p.G12C (CodeBreaK 202)

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: This trial evaluates the efficacy of sotorasib targeting KRAS p.G12C in combination with carboplatin and pemetrexed, compared to pembrolizumab with the same chemotherapy regimen, for treatment-naive patients with stage IV or advanced stage IIIB/C nonsquamous NSCLC with KRAS p.G12C mutations and no PD-L1 expression.

ClinicalTrials.gov ID: NCT05920356

A Phase 1, First-In-Human, Multicenter, Open-Label, Study of GQ1001, a HER2 Targeted Antibody-Drug Conjugate, Administered Intravenously, in Adult Patients With HER2-Positive Advanced Solid Tumors

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: This trial enrolls adult patients with HER2-positive advanced/unresectable or metastatic solid tumors that are relapsed or refractory to standard therapies, administering GQ1001, an antibody-drug conjugate targeting HER2 by combining trastuzumab with DM1. The study seeks to establish the safety and efficacy of escalating doses of GQ1001, with common adverse events including elevated liver enzymes, thrombocytopenia, and fever.

ClinicalTrials.gov ID: NCT04450732

A Phase 1a/1b Study to Evaluate the Safety and Tolerability of STK-012 As a Single Agent and in Combination Therapy in Patients with Selected Advanced Solid Tumors

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: This trial involves patients with advanced solid tumors, including NSCLC and RCC, who have progressed after or are intolerant to standard treatments, examining STK-012, an α/β-biased IL-2 partial agonist targeting CD25+ T cells, as a single agent and in combination with pembrolizumab, pemetrexed, and carboplatin.

ClinicalTrials.gov ID: NCT05098132

A Phase 1/1b Open-label, Multicenter Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of KIN-2787 in Participants With BRAF and/or NRAS Mutation-positive Solid Tumors.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: This trial is for adult patients with advanced or metastatic solid tumors harboring BRAF Class I, II, or III alterations, or NRAS mutations, and involves treatment with KIN-2787, a pan-RAF kinase inhibitor, as monotherapy or in combination with the MEK inhibitor binimetinib.

ClinicalTrials.gov ID: NCT04913285

Single Arm Study to Assess the Immune Effects of Fermented Wheat Germ (FWG) Nutritional Supplementation in Patients With Advanced Malignancies Being Treated With Standard of Care Checkpoint Inhibitor-Based Therapy

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: This trial involves adult patients with advanced solid tumor malignancies—specifically non-small cell lung carcinoma, renal cell carcinoma, melanoma, colorectal carcinoma, and triple-negative breast cancer—receiving fermented wheat germ supplementation alongside standard checkpoint inhibitor-based immunotherapy to assess immune-enhancing effects.

ClinicalTrials.gov ID: NCT05967533